Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China

View Full Paper
Ask AI
Bookmark
Share

Authors

ZPZhao Peiqi

Discussion

Loading...

Member takes

Overview

Real-world study shows polatuzumab vedotin improves complete response rates in high-risk DLBCL, suggesting potential as an effective treatment.

Key Points

  • This study aimed to evaluate the effectiveness and safety of polatuzumab vedotin combined with zuberitamab and standard chemotherapy in DLBCL.
  • Retrospective analysis of untreated adult DLBCL patients treated with polatuzumab vedotin and zuberitamab at Tianjin Medical University.
  • Response assessed using 2014 Lugano response criteria; primary outcome was complete response rate (CRR).
  • Secondary outcomes included objective response rate (ORR) and treatment-emergent adverse events (TEAEs).
  • Pola-Hi-CHP achieved a CRR of 83.3% among 72 evaluable patients, with an ORR of 100%.
  • Significant variation in CRR based on risk factors such as age, cell-of-origin, and IPI score.
  • Common grade ≥3 adverse events included leukopenia (29.2%) and neutropenia (38.9%).

Cite This Study

Zhao Peiqi (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db7ehttps://doi.org/10.1182/blood-2025-2747
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025
  2. 2Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study2025
  3. 3The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study2025
  4. 4Real-World Comparative Analysis of Polatuzumab Vedotin–Based Pola-R-CHP Versus Standard R-CHOP in Diffuse Large B-Cell Lymphoma: A Propensity Score–Matched Cohort Study2025
  5. 5Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data2025